PT1311488E - Imidazóis substituídos utilizados como inibidores de tafia - Google Patents

Imidazóis substituídos utilizados como inibidores de tafia Download PDF

Info

Publication number
PT1311488E
PT1311488E PT01954264T PT01954264T PT1311488E PT 1311488 E PT1311488 E PT 1311488E PT 01954264 T PT01954264 T PT 01954264T PT 01954264 T PT01954264 T PT 01954264T PT 1311488 E PT1311488 E PT 1311488E
Authority
PT
Portugal
Prior art keywords
substituted imidazoles
tafia inhibitors
tafia
inhibitors
imidazoles
Prior art date
Application number
PT01954264T
Other languages
English (en)
Inventor
John Steele
Julian Blagg
Mark Edward Bunnage
Charlotte Moira Norfo Allerton
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020346A external-priority patent/GB0020346D0/en
Priority claimed from GB0027409A external-priority patent/GB0027409D0/en
Priority claimed from GB0029556A external-priority patent/GB0029556D0/en
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PT1311488E publication Critical patent/PT1311488E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
PT01954264T 2000-08-17 2001-08-08 Imidazóis substituídos utilizados como inibidores de tafia PT1311488E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0020346A GB0020346D0 (en) 2000-08-17 2000-08-17 Pharmaceuticals
GB0027409A GB0027409D0 (en) 2000-11-09 2000-11-09 Pharmaceuticals
GB0029556A GB0029556D0 (en) 2000-12-04 2000-12-04 Pharmaceuticals

Publications (1)

Publication Number Publication Date
PT1311488E true PT1311488E (pt) 2009-12-30

Family

ID=27255849

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01954264T PT1311488E (pt) 2000-08-17 2001-08-08 Imidazóis substituídos utilizados como inibidores de tafia

Country Status (38)

Country Link
EP (1) EP1311488B1 (pt)
JP (2) JP4119746B2 (pt)
KR (1) KR20030022412A (pt)
CN (1) CN1443173A (pt)
AP (1) AP1375A (pt)
AR (1) AR035580A1 (pt)
AT (1) ATE447557T1 (pt)
AU (1) AU2001276605A1 (pt)
BG (1) BG107330A (pt)
BR (1) BR0113289A (pt)
CA (1) CA2419633C (pt)
CY (1) CY1109693T1 (pt)
CZ (1) CZ2003388A3 (pt)
DE (1) DE60140368D1 (pt)
DK (1) DK1311488T3 (pt)
DO (1) DOP2001000233A (pt)
EA (1) EA005532B1 (pt)
EE (1) EE200300070A (pt)
ES (1) ES2334101T3 (pt)
HR (1) HRP20030103A2 (pt)
HU (1) HUP0303763A3 (pt)
IL (1) IL153225A0 (pt)
IS (1) IS6638A (pt)
MA (1) MA26940A1 (pt)
MX (1) MXPA03001425A (pt)
NO (1) NO20030706L (pt)
NZ (1) NZ522823A (pt)
OA (1) OA12362A (pt)
PA (1) PA8525401A1 (pt)
PE (1) PE20020352A1 (pt)
PL (1) PL361054A1 (pt)
PT (1) PT1311488E (pt)
SI (1) SI1311488T1 (pt)
SK (1) SK1732003A3 (pt)
SV (1) SV2002000602A (pt)
TN (1) TNSN01126A1 (pt)
UY (1) UY26889A1 (pt)
WO (1) WO2002014285A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
EP1467731A1 (en) * 2002-01-22 2004-10-20 Pfizer Limited 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
JP2005516972A (ja) * 2002-01-22 2005-06-09 ファイザー・インク 血栓疾患の治療のためのｔａｆｉ−ａ阻害剤として使用される３−（イミダゾリル）−２−アミノプロピオン酸
US8512675B2 (en) 2003-04-29 2013-08-20 Mallinckrodt Llc N and/or Nα derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3 (CO)3]+ by fac coordination
SE0302853D0 (sv) * 2003-10-29 2003-10-29 Astrazeneca Ab Chemical compounds
ZA200603165B (en) * 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
JP2008536923A (ja) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心筋の再灌流の増強およびｐｃｉの容易化のためのｔａｆｉ阻害剤の使用
DE102005049385A1 (de) * 2005-10-15 2007-04-19 Sanofi-Aventis Deutschland Gmbh Imidazolderivate als Inhibitoren von TAFIa
NZ577312A (en) * 2006-12-06 2012-02-24 Sanofi Aventis Urea and sulfamide derivatives as tafia inhibitors
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
EP2361910A4 (en) * 2008-10-29 2012-08-01 Taisho Pharmaceutical Co Ltd CONNECTION WITH TAFIA-INHIBITOR EFFECT
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
LT2548871T (lt) * 2010-03-18 2017-09-25 Daiichi Sankyo Company, Limited Cikloalkilpakeistieji imidazolo dariniai
CN102884053B (zh) 2010-03-18 2016-03-02 第一三共株式会社 环丙烷甲酸衍生物
PE20141161A1 (es) * 2011-05-17 2014-10-01 Pharmasyntez Los compuestos para el tratamiento y la prevencion de la adhesion, las composiciones farmaceuticas relacionados con el compuesto y los metodos para la prevencion y el tratamiento de adherencias
DK2734508T3 (en) * 2011-07-22 2018-05-22 Cambrex Karlskoga Ab NEW PROCEDURES FOR THE PREPARATION OF 4-SUBSTITUTED IMIDAZOLS
WO2013039202A1 (ja) * 2011-09-15 2013-03-21 第一三共株式会社 新規アクリル酸誘導体
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
DK3359528T3 (en) 2015-10-07 2022-03-07 Mitobridge Inc Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3437641A4 (en) * 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
KR102430906B1 (ko) * 2016-04-13 2022-08-10 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6163661A (ja) * 1984-09-05 1986-04-01 Microbial Chem Res Found ヒスタジン関連化合物
US5993815A (en) * 1996-11-08 1999-11-30 University Of Vermont Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
CA2419633C (en) 2011-05-10
ES2334101T3 (es) 2010-03-05
TNSN01126A1 (fr) 2005-11-10
AU2001276605A1 (en) 2002-02-25
HRP20030103A2 (en) 2003-04-30
DOP2001000233A (es) 2002-05-15
EA200201239A1 (ru) 2003-08-28
JP4119746B2 (ja) 2008-07-16
NO20030706L (no) 2003-04-15
PA8525401A1 (es) 2002-04-25
SV2002000602A (es) 2002-10-24
DK1311488T3 (da) 2010-01-04
PE20020352A1 (es) 2002-05-11
JP2004506044A (ja) 2004-02-26
CZ2003388A3 (cs) 2004-03-17
EA005532B1 (ru) 2005-04-28
IS6638A (is) 2002-11-28
WO2002014285A1 (en) 2002-02-21
IL153225A0 (en) 2003-07-06
KR20030022412A (ko) 2003-03-15
ATE447557T1 (de) 2009-11-15
OA12362A (en) 2004-04-07
HUP0303763A2 (hu) 2004-04-28
DE60140368D1 (de) 2009-12-17
EP1311488B1 (en) 2009-11-04
AP1375A (en) 2005-03-03
AR035580A1 (es) 2004-06-16
SK1732003A3 (en) 2004-08-03
JP4778531B2 (ja) 2011-09-21
NZ522823A (en) 2004-11-26
UY26889A1 (es) 2002-03-22
NO20030706D0 (no) 2003-02-14
EP1311488A1 (en) 2003-05-21
MA26940A1 (fr) 2004-12-20
SI1311488T1 (sl) 2010-01-29
AP2001002250A0 (en) 2001-09-30
PL361054A1 (en) 2004-09-20
CN1443173A (zh) 2003-09-17
EE200300070A (et) 2005-02-15
HUP0303763A3 (en) 2004-06-28
CY1109693T1 (el) 2014-08-13
CA2419633A1 (en) 2002-02-21
BR0113289A (pt) 2003-06-17
BG107330A (en) 2003-06-30
MXPA03001425A (es) 2003-06-06
JP2008169224A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
IL153225A0 (en) Substituted imidazoles as tafia inhibitors
HK1061030A1 (en) Rho-kinase inhibitors
HK1061029A1 (en) Rho-kinase inhibitors
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
IL148614A0 (en) Pteridinones as kinase inhibitors
IL153787A0 (en) Imidazole derivatives
HUP0301181A2 (en) Imidazole derivatives as raf kinase inhibitors
GB9900416D0 (en) Inhibitors
AU3704101A (en) Kinase inhibitors
HK1091492A1 (en) Hydantoin derivatives as mmp inhibitors
IL150114A0 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
PL362564A1 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
EP1153022A4 (en) PROTEASE INHIBITORS
IL162677A0 (en) 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
HK1049999B (zh) 咪唑類衍生物
SG127755A1 (en) Imidazoline compounds
GB0029730D0 (en) Inhibitors
GB0029733D0 (en) Inhibitors
GB0021193D0 (en) Inhibitors
GB0015996D0 (en) Inhibitors
ZA200405344B (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors.
SI1318992T1 (sl) Derivati imidazola kot inhibitorji raf-kinaze
GB9929341D0 (en) Inhibitors
GB9929340D0 (en) Inhibitors
GB9917294D0 (en) Inhibitors